Menu
Back to Journals » Cancer Management and Research » Volume 5
Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases
Authors Longo J, Lutz S, Johnstone C
Received 25 April 2013
Accepted for publication 1 July 2013
Published 13 August 2013 Volume 2013:5 Pages 235—242
DOI https://doi.org/10.2147/CMAR.S35789
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
John Longo,1 Stephen Lutz,2 Candice Johnstone1
1Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 2Department of Radiation Oncology, Blanchard Valley Regional Cancer Center, Findlay, OH, USA
Abstract: Bone metastases are prevalent among cancer patients and frequently cause significant morbidity. Oncology providers must mitigate complications associated with bone metastases while limiting therapy-related adverse effects and their impact on quality of life. Multiple treatment modalities, including chemotherapy, surgery, external beam radiation therapy, and radioisotopes, among others, have been recommended and utilized for palliative treatment of bone metastases. Radioisotopes such as samarium-153 are commonly used in the setting of multifocal bone metastases due to their systemic distribution, affinity for osteoblastic lesions, acceptable toxicity profile, and convenience of administration. This review focuses on samarium-153, first defining its radiobiologic and pharmacokinetic properties before describing many clinical trials that support its use as a safe and effective tool in the palliation of patients with bone metastases.
Keywords: bone metastases, pain, radiopharmaceuticals, pain flare
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.